Urispas is a prescription medication specifically formulated to provide targeted relief from urinary bladder spasms and associated discomfort. As an antispasmodic agent containing flavoxate hydrochloride, it works directly on the smooth muscle of the urinary tract to reduce involuntary contractions. This medication is particularly valuable for patients experiencing symptoms related to various urological conditions, offering a specialized approach to managing urinary urgency, frequency, and pain. Medical professionals often recommend Urispas as part of a comprehensive treatment plan for bladder dysfunction.

Features

• Contains flavoxate hydrochloride as the active pharmaceutical ingredient
• Available in convenient 100mg tablet formulation
• Exhibits direct smooth muscle relaxant properties on the urinary tract
• Provides localized action with minimal systemic effects
• Manufactured under strict pharmaceutical quality control standards
• Packaged with appropriate patient information leaflets

Benefits

• Effectively reduces painful bladder spasms and associated discomfort
• Decreases urinary urgency and frequency, improving quality of life
• Allows for better bladder control and reduced incontinence episodes
• Helps restore normal urinary patterns without sedation
• Provides targeted relief with a well-established safety profile
• Complements other urological treatments when used as directed

Common use

Urispas is primarily indicated for the symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency, and incontinence associated with various urological conditions. These include cystitis, prostatitis, urethritis, and urethrocystitis/urethrotrigonitis. It is particularly useful in managing symptoms of overactive bladder and interstitial cystitis. Medical practitioners may also prescribe Urispas following urological surgical procedures or instrumentation to alleviate postoperative bladder spasm and discomfort.

Dosage and direction

The recommended adult dosage is one 100mg tablet three or four times daily. The tablets should be swallowed whole with a full glass of water, with or without food, though taking with food may minimize potential gastrointestinal discomfort. Dosage should be individualized based on symptom severity and patient response. Treatment duration varies depending on the underlying condition and symptom improvement. Patients should not exceed the prescribed dosage without medical consultation. Elderly patients may require dosage adjustment based on renal function.

Precautions

Patients with glaucoma should use Urispas with caution and under close medical supervision. Those with gastrointestinal obstruction, intestinal atony, or severe ulcerative colitis require careful monitoring while taking this medication. Individuals with hepatic or renal impairment may need dosage adjustments. Caution is advised when operating machinery or driving until the patient’s response to the medication is known. Regular follow-up with healthcare providers is recommended to assess treatment efficacy and potential side effects.

Contraindications

Urispas is contraindicated in patients with known hypersensitivity to flavoxate hydrochloride or any component of the formulation. It should not be used in individuals with gastrointestinal hemorrhage, mechanical obstructive conditions of the gastrointestinal tract, or ileus. The medication is contraindicated in patients with obstructive uropathy and significant urinary retention. It is not recommended for use in children under 12 years of age due to insufficient safety and efficacy data in this population.

Possible side effect

Common side effects may include nausea, vomiting, dry mouth, blurred vision, dizziness, drowsiness, headache, and nervousness. Some patients may experience gastrointestinal discomfort, constipation, or difficulty urinating. Less frequently reported effects include skin rash, itching, increased intraocular pressure, palpitations, and tachycardia. These effects are generally mild and often diminish with continued therapy. Patients should report persistent or severe side effects to their healthcare provider promptly.

Drug interaction

Urispas may enhance the effects of other anticholinergic drugs, potentially increasing side effects. Concurrent use with CNS depressants including alcohol, sedatives, and tranquilizers may result in additive sedation. The medication may affect gastrointestinal motility and potentially alter the absorption of other orally administered drugs. Patients should inform their healthcare providers about all prescription medications, over-the-counter drugs, and herbal supplements they are taking to avoid potential interactions.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed one. Maintaining consistent dosing intervals helps ensure optimal therapeutic效果. If multiple doses are missed or uncertainty exists about proper dosing, patients should consult their healthcare provider or pharmacist for guidance.

Overdose

Symptoms of overdose may include severe anticholinergic effects such as blurred vision, excessive dry mouth, difficulty swallowing, hot dry skin, tachycardia, and CNS disturbances including confusion, agitation, and hallucinations. In severe cases, respiratory depression and cardiovascular collapse may occur. Treatment is primarily supportive and symptomatic. Gastric lavage may be considered if ingestion was recent. Activated charcoal may be administered. Patients suspected of overdose should seek immediate medical attention.

Storage

Store at room temperature between 15-30°C (59-86°F) in a dry place protected from light and moisture. Keep the medication in its original container with the lid tightly closed. Do not store in bathroom areas where moisture levels fluctuate. Keep out of reach of children and pets. Properly discard any expired or unused medication according to local regulations. Do not flush medications down the toilet unless specifically instructed to do so.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Individual patient needs may vary, and healthcare providers should make treatment decisions based on their clinical judgment. Patients should always follow their prescribed treatment plan and consult their healthcare provider with any questions or concerns about their medication. The complete prescribing information should be consulted before initiating therapy.

Reviews

Clinical studies demonstrate that Urispas provides effective symptomatic relief for approximately 70-80% of patients with bladder spasm-related symptoms. Many patients report significant improvement in urinary frequency and urgency within the first week of treatment. Medical professionals appreciate its targeted action and generally favorable side effect profile compared to broader anticholinergic agents. Long-term users note consistent efficacy when used as part of a comprehensive bladder management program. Some patients report the need for dosage adjustment to optimize benefits while minimizing side effects.